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Welcome from the CCE XV Chairs 
 
Welcome everyone to La Quinta for the 15th Cell Culture Engineering (CCE) conference!  
For three decades, this series has established a reputation as one of the premiere cell 
culture engineering conferences and has had a significant impact on the direction of cell 
culture technologies and on biotechnology industry growth. Throughout this time, the CCE 
series has also been the main forum where industry and academia met to assess the 
science and technology progress in the field and to guide trends and establish good 
practices.  
 
With 400 participants from 25 countries on 5 continents, this year’s meeting is certainly 
one of the largest ECI conferences ever, and one of the most diverse to date involving 
many students, academics, government, and industry representatives to invest in the 
future and sustain the growth of the cell culture engineering industry. This was only 
possible because of generous donations from about fifty industrial partners. The program 
includes 50 oral presentations, plus four keynote addresses.  In addition, we have nine 
thematic workshops and ~ 200 posters.  As it has been the tradition and a key success 
factor of this conference series, a significant amount of time has been allocated to poster 
sessions. You are invited and strongly encouraged to take full advantage of this 
opportunity to explore and discuss the large body of interesting and excellent work that 
will be presented in these sessions. 
 
Global sales of biologics continue to increase, with sales for 2015 estimated at >$200 
billion (US $). These biologics products include recombinant proteins, monoclonal 
antibodies, antibody fusion proteins, antibody drug complexes, and other antibody-like 
complex proteins, and are still mainly expressed in mammalian cells.  In particular, 
monoclonal antibodies and antibody fusion proteins continue to be the best-selling class 
of biologics, with all the top sellers manufactured using large scale mammalian cell 
cultures.  The past two years has seen new antibodies commercialized as part of the 
introduction of cancer immunotherapies.  We’ve also seen the the FDA’s first approval of 
a biosimilar in March 2015.  And, importantly for patients, we’ve also seen multiple 
products approved extremely rapidly following breakthrough therapy pathways 
established by regulators.  Now, more than ever, the mammalian cell culture field must 
focus efforts on rapid establishment of high producing cell lines, development, scale-up 
and implementation of robust manufacturing processes to support rapid launches and 
reliable supplies of these commercial products.  At the same time, many biosimilar 
products are being developed and introduced into the market, which will intensify these 
efforts.  Beyond accelerated timeline and process intensification for higher productivities 
and improved product quality, efforts must also address the need to deliver cost-effective 
manufacturing of biologics, particularly in terms of reaching additional markets previously 
unserved by these powerful medicines in addition to responding to the potential pricing 
pressures driven by biosimilars.  With this in mind, we’ve put a program together which 
will showcase new directions, challenges, and successes in the cell culture engineering 
arena, as shared by leading academic and industrial experts. In addition to addressing 
challenges related to development of novel protein biologics, we will continue the efforts 
to address the future of cell culture engineering beyond protein biologics. We know this 
will facilitate information exchange on how cell culture engineering principles derived from 
the development of novel biologics products are applicable to development of biosimilars 
and cell therapy products, particularly in terms of flexibility, high productivity, low costs, 
and consistent product quality.  Additionally, we have introduced an oral session on 
“Current Concerns”, with which we aim to highlight the most current challenges facing our 
community, be they derived from business, technical, or regulatory origin.  We strongly 
encourage each and every one of you to engage in the dialogue that is enabled by this 
conference venue, sharing your thoughts and expertise with others as we collectively 
shape the future of cell culture engineering.   
 
We invite you to enjoy the Palm Springs area.  We also invite you to enjoy your stay at the 
La Quinta resort, a full-service resort that offers many opportunities to enjoy recreation or 
relaxation.  This resort is large enough to comfortably accommodate all attendees within 
the same location, which we highly valued as an important element of creating the desired 
atmosphere for a CCE conference.  In listening to the feedback from prior conferences, 
we have arranged the schedule so as to provide you with a large chunk of free time on 
Tuesday afternoon, and we hope you will take advantage of the many opportunities to 
explore the Palm Springs area, or just take the opportunity to refresh and relax on the 
grounds of this lovely resort with its extensive swimming pools, tennis courts, golf, and 
health spa.  We look forward to having you all at a memorable gala dinner where we will 
recognize the next winner of the Cell Culture Engineering award, recognize some of the 
outstanding posters presented here, learn of the chairs for the next CCE to be held in 
2018, and enjoy our last opportunity together to network and enjoy the camaraderie of our 
incredible cell culture community.   
 
We would like to thank all of the oral session chairs, workshop program and session chairs, 
and poster session chairs, all of whom have worked with a remarkable dedication to put 
together a balanced and high quality program.  And, once again, thanks to the corporate 
sponsors for enabling our outstanding academic attendance. 
 
We would also like to convey to our cell culture community a message of regret at not 
having been able to accept many colleagues from Academia and Industry who were 
interested to participate in this event. Clearly, this conference continues to be in high 
demand.  But, the implicit working principle of keeping the conference with a size of 
participants that would maximize interactions among scientists and engineers while still 
allowing efficient cross fertilization between different sectors makes it difficult to 
accommodate all requests to attend.   
 
Finally, special thanks to Barbara Hickernell and her dedicated team at ECI, particularly 
Kathy Chan, Kevin Korpics, and Tressa D’Ottavio for their tireless help and enormous 
assistance with the logistics and details. Certainly, many of you received personalized 
emails from Kathy in managing the invitation and registration process.  We hope that this 
conference will live up to the high standard that has been set for the CCE series by 
preceding Chairs.  On that note, we have embarked on a new technological milestone for 
CCE – that of moving to a primarily electronic-based program format.  We have made this 
decision based on an interest to reduce the use of paper and the cost of printing massive 
program books, while still giving you full access to oral and poster abstracts.  This is a bit 
of an experiment for the first time, so we hope you will bear with us as we move the 
technology forward based on the benefits it can deliver.   
 
Once again, welcome to La Quinta and the Palm Springs area, and a warm (no pun 
intended) welcome to Cell Culture Engineering XV. We look forward to meeting each of 
you personally.  
 
Bob Kiss, Sarah Harcum, and Jeff Chalmers 
Chairs, Cell Culture Engineering XV 
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2016 Cell Culture Engineering Award Winner 
 
Konstantin B. Konstantinov 
 
Konstantin Konstantinov has served the cell culture community for over two decades with pioneering contributions to the 
field and through his leadership and vision for the future.  He was instrumental in the 
development of perfusion cultivation processing which has been incorporated into current 
commercial processes, and his vision for integrated continuous bioprocessing has profoundly 
altered the landscape and future of cell culture bioprocessing and biopharmaceutical 
manufacturing.  Konstantin has been involved in the process development and commercial 
support of many biotherapeutics including Kogenate®, Kogenate-FS®, Myozyme®, 
Cerezyme®, Fabrazyme®, Thyrogen®, Campath/Lemtrada, BAY 81-8973, and BAY 94-9027.  
While his impact to the industry has been transformational, Konstantin has also been an 
important contributor to the cell culture literature as well with over 50 peer-reviewed 
publications. He has given over 150 conference presentations, reflecting his openness in 
sharing advances with the larger community.  He has also chaired the Cell Culture Engineering 
conference, together with James Piret, and was the visionary and one of the founders of the 
highly successful ECI series on Integrated Continuous Biomanufacturing. He has continued to make sustained contributions 
to the cell culture community by co-chairing sessions and serving as an active member of the CCE steering committee. 
Among his most significant contributions community are:  
 Advanced Process Control of Perfusion Processes: Konstantin recognized that next-generation manufacturing 
processes could be substantially more sophisticated and he formulated a long-term vision which began with rigorous 
process monitoring and the evaluation of novel on-line sensors followed by early laboratory-scale proof of concept 
demonstrations.  The latest iteration of the control system Konstantin pioneered is currently in use at Bayer both in 
process development labs and for GMP manufacturing of clinical material. 
 Perfusion Process Development: No other individual in the cell culture community has influenced perfusion 
process development more than Konstantin.  His group was the first to successfully demonstrate large-volume 
cryobag preservation of cells, considerably shortening seed-train expansion.  Konstantin’s group came up with an 
ingenious buffering system which reduced bioreactor pCO2 by ~70%. dditionally, Konstantin was central to the 
advancement of Bayer’s cell retention technology, recognized by the ACS Industrial Biotechnology Award in 2004. 
 Integrated Continuous Biomanufacturing:  Konstantin has pioneered the concept of extending continuous 
manufacturing to downstream processing and ultimately all the way to drug product manufacturing. For instance, 
his group demonstrated volumetric productivities about 10 times higher than current commercially licensed fed-
batch processes.  Higher productivities can considerably reduce the footprint of a manufacturing facility and capital 
costs.  
 Mentorship: Attracting and nurturing talent has been another defining attribute of Konstantin’s career. This is 
perhaps best exemplified by the success of former members of his cell culture group at Bayer whose success 
makes Konstantin’s contribution unique in the cell culture field.  
This prestigious award recognizes outstanding contributions to the field of Cell Culture and is given bi-annually at the ECI 
Cell Culture Engineering conference. Former recipients are Wei-Shou Hu (2002), Eleftherios T. Papoutsakis (2004), W. 
Robert  Arathoon (2006), Martin Fussenegger (2008), Michael J. Betenbaugh (2010), James M. Piret (2012), and Jeffrey J. 
Chalmers (2014). 
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2016 Martin Sinacore Award Winner 
 
 
 
Huong Le 
 
 
Huong Le is the 2016 winner of the Martin Sinacore Outstanding Young Investigator Award.  She joined 
the Process Development group at Amgen in 2012 after completion of a Chemical Engineering Ph.D. at the 
University of Minnesota. In her Ph.D. work she introduced advanced data mining to unveil hidden process 
characteristics from biomanufacturing data. Her work on systems analysis of transcriptome data helped 
advance transcriptomic applications in biopharmaceutical science. With her insight on transcriptomics she 
demonstrated a novel concept of dynamic cell engineering using endogenous promoters with various dy-
namics of expression profiles.  
 
At Amgen, Huong continued engaging in first-principle based approaches to biopharmaceutical processes 
development despite the complexity and rigor associated with this approach, all while fully engaging in the 
core responsibility of advancing innovative programs in Amgen’s early-stage pipeline. Recognizing gaps in 
reference sequence utilization for CHO transcriptomic studies, Huong led an effort to compare available 
public genomic references which resulted in an important recommendation for the approach of choice.  
 
Furthermore, she has co-developed an integrated and automated transcriptomics analysis pipeline which 
substantially reduces the time and effort to analyze RNA-Seq data. Huong has extensively characterized 
intrinsic variability associated with metabolomic data in CHO cells and has shown that technical variability 
can surpass biological variability, highlighting the need to account for this variability during biological inter-
pretation of -omics data. Collectively, her research efforts can accelerate wider adoption of omics-based 
approaches analysis to facilitate mechanism-driven biopharmaceutical cell line development and process 
optimization.  
 
In addition to engaging in high quality first principles-based research over her ~4-year industrial career, 
Huong has played a key-role in the advancement of multiple innovative molecules in Amgen’s early-stage 
pipeline, several of which have resulted in successful IND filings.  
 
 
The Martin Sinacore Outstanding Young Investigator Award was established by ECI and Biogen to pay 
tribute to the many contributions Marty Sinacore made to the cell culture and bioprocessing community 
over the course of his productive thirty-year career.  Although we have lost an influential thought leader, his 
influence will be felt for years to come given the role Marty played in shaping the way we approach the 
challenge of developing new therapeutics.  Working with pre-adapted host cells, high throughput analytics 
to enable product quality assessments early in cell line development and the adoption of “omics” technology 
to improve bioprocessing are common place today thanks in part to the innovative vision Marty brought to 
the field over the years.   
Beyond being a productive scientist, Marty will also be remembered for his genuine warmth and ability to 
connect with people of all types.  He was deeply committed to working collaboratively and breaking down 
barriers so that common problems could be effectively solved.  To this end, he formed the MassBio Up-
stream Process Development Forum to provide a venue in which the Boston bioprocessing community 
could come together and share ideas.   
His true passion however was sharing his knowledge, experiences and insights with junior scientists to help 
them grapple with challenging problems and grow as scientists.  It is with this spirit in mind that the award 
has been created; to not only celebrate the immeasurable impact Marty’s mentorship has had on the ca-
reers of many young scientists but also acknowledge the accomplishments and exceptional promise of the 
recipients. 
Previous winners of this award are Colin Clarke (Dublin City University, Ireland) and Corinne Hoesli 
(McGill University, Canada). 
Conference Sponsors 
The organizers wish to express their gratitude to the following companies who, through their 
generosity, have helped to make this conference possible. 
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Pfizer Inc. 
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Thermo Fisher Scientific 
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Bristol-Myers Squibb 
Eppendorf, Inc. 
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Gilead Sciences 
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Merck and Co., Inc. 
UCB Pharma SA 
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Applikon Biotechnology, Inc.   
Celgene 
GE Healthcare 
Irvine Scientific 
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Silver 
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Novo Nordisk A/S 
Solentim Ltd 
Takeda 
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Ajinomoto Co., Inc. 
Alexion Pharmaceuticals 
Aspen Brook 
Bayer Healthcare 
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Boehringer Ingelheim 
Chugai Pharmaceutical Co. Ltd.  
Cipla BioTec 
Cook Pharmica LLC 
FUJIFILM Diosynth Biotechnologies 
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Janssen Research & Development 
Kuhner Shaker Inc. 
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Seattle Genetics 
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Thomson Instrument Company 
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Xell AG 
Room locations and notes 
 
 
• General sessions will be held in the Fiesta Ballroom. 
• Poster Sessions will be in the Flores Ballroom. All posters will remain mounted for the 
entire conference. Authors of even-numbered posters are asked to stay with their 
presentations on Sunday and Tuesday evenings, and authors of odd-numbered posters 
are asked to stay with their presentations on Monday and Wednesday evenings. 
 Posters must be taken down no later than 9:00 am on Thursday morning. 
• The locations for workshops and parallel sessions are listed in the program. 
• All breakfasts and lunches will be in the All Grass Area. 
• Dinner locations are listed in the program. 
• Coffee breaks will be in Fiesta Veranda. 
• Audiotaping, videotaping and photography of presentations are strictly prohibited. 
• Speakers – Please leave at least 5 minutes for questions and discussion. 
• Please do not smoke at any conference functions. 
• The ECI office is in the Flores Office B and C. 
• The Fountain Room is available for small ad hoc meetings during the week. Please see 
ECI staff if you would like to schedule a meeting. 
• Turn your cellular telephones to vibrate or off during technical sessions. 
• Please write your name in the front of this booklet in case it is misplaced. 
• Be sure to check the participant list in this booklet to confirm that your listing is correct. If 
there are changes or updates, please login to the ECI website and update your listing so 
that the list that ECI will send to all participants after the conference will be correct. 
 
 
Sunday, May 8, 2016 
 
1:00 PM – 5:00 PM             Conference Check-in (Flores Foyer) 
3:00 PM – 4:30 PM             Workshops (3 in parallel) 
  
Workshop 1: Advances in cell line engineering and protein expression 
strategies  (Flores 6, 7, 8) 
Facilitators: Trent Munro (Amgen) and Richard Schwartz (NIH) 
Sponsored by UCB Pharma SA 
 
Workshop 2: Increasing speed to the clinic while ensuring future 
manufacturability   (Fiesta 10, 13, 14) 
Facilitators: Suzanne Farid (UCL) and Steven Lang (Janssen 
Biotherapeutics) 
Sponsored by Gilead Sciences 
 
Workshop 3: Advances in analytical methods and their use for process 
characterization  (Fiesta 9, 11, 12) 
Facilitators: Claudia Buser (Sanofi) and Rao Kandula (Celgene) 
Sponsored by Biomarin 
 
4:45 PM – 5:30 PM         Opening Remarks (Fiesta) 
    Conference Chairs: Robert Kiss, Sarah Harcum, Jeff Chalmers 
    ECI Technical Liaison: Mike Betenbaugh 
Native American Dance Performance – Eric Runningpath  
  
5:30 PM – 6:30 PM              Keynote – Ira Mellman (Genentech) 
The renaissance of cancer immunotherapy is a revolution for 
patients 
  
6:45 pm - 8:15 pm                Dinner (La Casa)  
 
8:30 PM – 10:30 PM           Poster Session (Authors of even-numbered posters are asked to 
stay with their posters)  
    Sponsored by Applikon Biotechnology, Inc. and Celgene 
 
  
Monday, May 9, 2016 
 
6:30 AM – 8:00 AM             Breakfast Buffet 
      
Organizing Committee Breakfast Meeting (The Studios) 
 
8:00 AM – 9:55 AM             Session 1: Novel Protein Formats & Technologies 
     Sponsored by Genentech 
 
8:00 AM – 8:05 AM  Introduction – Session Chairs 
         John Joly (Genentech) 
         Jennifer Maynard (University of Texas, Austin) 
  
8:05 AM – 8:15 AM  Poster Highlights  
8:05 AM Poster Highlight for Novel Protein Formats (Session 1): 
Alyssa Powell (Ambrx) 
Antibody production with site-specific non-natural amino acid 
incorporation for generation of antibody drug conjugates 
 
8:10 AM Poster Highlight for Non-Protein Products (Session 9): 
Suzanne S. Farid (University College London) 
Cell therapy manufacturing strategies: Impact on cost of goods, cost of 
development and commercialization 
 
8:15 AM – 8:40 AM  Talk 1: Steven Lang (Janssen R&D) 
        Building quality novel formats and development processes 
 
8:40 AM – 9:05 AM   Talk 2: Jennitte Stevens (Amgen) 
Engineering, expression screening, and production cell line development 
of hetero Ig molecules using charge pair mutations 
  
9:05 AM – 9:30 AM  Talk 3: Christoph Spiess (Genentech) 
        Bispecific antibodies: Strategies, considerations and challenges 
  
9:30 AM – 9:55 AM  Talk 4: Pierre Moretti (Glenmark Pharma) 
A novel bispecific antibody for HER2+ breast cancer: The BEAT GBR 
1302 
 
10:00 AM – 10:30 AM         Coffee Break / Networking 
  
10:30 AM – 11:15 AM  Keynote – Stephen Hadley (Gates Foundation) 
Challenges developing biologics for the prevention and treatment 
of infectious diseases impacting global health 
  
11:15 AM – 12:20 PM         Session 2a: Cell Line Development Advances 
  
11:15 AM – 11:20 AM  Introduction – Session Chairs 
Scott Estes (Codiak Biosciences) 
Alan Dickson (University of Manchester) 
  
 
 
 
Monday, May 9, 2016 (continued) 
 
11:20 AM – 11:30 AM  Poster Highlights  
11:20 AM Poster Highlight for Cell Line Development Advances 
(Session 2) 
Jae Seong Lee (Technical University of Denmark) 
Accelerated homology-directed targeted integration of transgenes in 
CHO cells via CRISPR/Cas9 and fluorescent enrichment 
 
11:25 AM Poster Highlight for Application of ‘Omics (Session 8): 
Hooman Hefzi (UCSD) 
A community genome-scale model of Chinese hamster ovary cell 
metabolism identifies differences in the efficiency of resource utilization 
for various bioprocesses 
  
11:30 AM – 11:55 AM  Talk 5: Wei-Shou Hu (University of Minnesota) 
Systems engineering of a CHO cell line for enhanced process 
robustness 
  
11:55 AM – 12:20 PM  Talk 6: Wei-Kuang Chi (Development Center for Biotechnology of 
    Taiwan) 
Omics approach for generating a high-yield CHO cell line producing 
monoclonal antibodies 
  
12:20 PM – 1:45 PM           Lunch 
  
1:45 PM – 3:30 PM            Session 2b: Cell Line Development Advances (continued) 
 
1:45 PM – 1:50 PM  Introduction – Session Chairs  
Scott Estes (Biogen) 
Alan Dickson (University of Manchester) 
  
1:50 PM – 2:15 PM  Talk 7: Nathan E. Lewis (University of California, San Diego) 
Predictive engineering of CHO cells using systems biology models 
  
2:15 PM – 2:40 PM  Talk 8: Helene Faustrup Kildegaard (Technical University of 
    Denmark) 
Generation of desirable CHO cell factories with predictive culture 
performance using CRISPR/Cas9-mediated genome engineering 
  
2:40 PM – 3:05 PM  Talk 9: Kerstin Otte (Biberach University of Applied Sciences) 
Effective microRNAs for cell line engineering and cellular mechanisms of 
action 
  
3:05 PM – 3:30 PM  Talk 10: Yongping Crawford (Genentech) 
Developing the host for targeted integration cell line development 
  
3:30 PM – 4:00 PM             Coffee Break / Networking 
  
4:00 PM – 6:20 PM             Session 3: Integrated Continuous Processing for Biologics 
  
4:00 PM – 4:05 PM  Introduction – Session Chairs 
Oscar Lara-Velasco (GSK) 
Laura Palomares (UNAM) 
Monday, May 9, 2016 (continued) 
 
4:05 PM – 4:15 PM  Poster Highlights  
4:05 PM Poster Highlight for Integrated Continuous Processing 
(Session 3) 
Daniel Vázquez (Max Planck Institute) 
Process optimization for semi-continuous virus production at high cell 
densities 
4:10 PM Poster Highlight for Applications of QbD & PAT  
(Session 10) 
Gene Schaefer (Janssen) 
Moving from a bioreactor scale-up/scale-down approach to a more 
holistic operational design space view 
  
4:15 PM – 4:40 PM  Talk 11: Udo Reichl (Max Planck Institute) 
Process optimization for semi-continuous virus production at high cell 
densities 
  
4:40 PM – 5:05 PM  Talk 12: Zhimei Du (Merck) 
Evolution of an integrated continuous antibody manufacturing process 
  
5:05 PM – 5:30 PM  Talk 13: Jason Walther (Sanofi) 
Overcoming process intensification challenges to deliver a 
manufacturable and competitive integrated continuous biomanufacturing 
platform 
  
5:30 PM – 5:55 PM  Talk 14: Gregory W. Hiller (Pfizer) 
Cell-controlled high-intensity perfusion and hybrid fed-batch systems that 
drastically reduce perfusion rates and harmonize with continuous 
downstream processing 
  
5:55 PM – 6:20 PM   Talk 15: Ricardo Silva (iBET) 
Purification of a hepatitis C vaccine candidate: Comparison between 
multi- column chromatographic processes operated in positive and 
negative mode 
 
6:30 PM – 8:30 PM             Dinner (Tennis Courtside) 
 
8:30 PM – 10:30 PM           Poster Session (Authors of odd-numbered posters are asked to 
stay with their posters) 
    Sponsored by GE Healthcare, Irvine Scientific and Kerry 
  
Tuesday, May 10, 2016 
  
6:30 AM – 8:00 AM             Breakfast Buffet 
  
8:00 AM – 10:15 AM             Session 4a: Current Concerns 
  
8:00 AM – 8:05 AM  Introduction – Session Chairs 
Tongtong Wong (Lilly) 
Jamey Young (Vanderbilt University) 
  
8:05 AM – 8:10 AM  Poster Highlight for Current Concerns (Session 4):  
Kelvin Lee (University of Delaware) 
A host cell protein that may impact polysorbate degradation 
  
8:10 AM – 8:35 AM  Talk 16: Beth Junker (Merck) 
Life in the fast lane: Developing and commercializing KEYTRUDA®, a 
novel breakthrough therapy designation oncology therapy, in three years 
from first patient dosed to US approval 
  
8:35 AM – 9:00 AM Talk 17: Nicole Borth (BOKU University of Natural Resources and 
Applied Life Sciences) 
To clone or not to clone? – Wrong question! An investigation on genome 
heterogeneity and stability and on what controls cell behavior 
  
9:00 AM – 9:25 AM  Talk 18: Brian E. Mickus (Gilead Sciences) 
Targeted sequencing for comprehensive genetic characterization of a 
recombinant CHO cell line 
  
9:25 AM – 9:50 AM  Talk 19: Christopher C. Frye (Eli Lilly) 
Polysorbate 20 and 80 degradation by Group XV lysosomal 
phospholipase A2 Isomer X1 in monoclonal antibody formulations 
 
9:50 AM – 10:15 AM  Talk 20: Kevin Kayser (SAFC) 
Genetic engineering of MMV virus resistance into CHO cells: Probing the 
role of various CHO sialyltransferases in virus binding and internalization 
 
10:15 AM – 10:45 AM         Coffee Break / Networking 
  
10:45 AM – 12:45 PM         Session 5: Scale-up and Scale-down Challenges 
  
10:45 AM – 10:50 AM  Introduction – Session Chairs 
Anurag Khetan (Bristol-Myers Squibb) 
Frank Chaplen (Oregon State University) 
  
10:50 AM – 10:55 AM Poster Highlight for Scale-up and Scale-down Challenges (Session 
5): 
Jin Yin (Sanofi) 
A holistic approach to the scale-up of a microcarrier-based perfusion cell 
culture process for the production of a therapeutic enzyme  
  
10:55 AM – 11:20 AM  Talk 21: Alex Doane (Biogen) 
Implementation of a recirculating TFF N-1 perfusion system at 
manufacturing scale: Conquering process hurdles and scaling 
challenges 
Tuesday, May 10, 2016 (continued) 
 
11:20 AM – 11:45 AM  Talk 22: Weili Wang (MaxCyte) 
Seamless scalability, consistency and quality of transient protein 
production in CHO Cells by using MaxCyte flow electroporation 
technology 
  
11:45 AM – 12:10 PM  Talk 23: Zizhuo Xing (Bristol- Myers Squibb) 
A carbon dioxide stripping model for mammalian cell culture in 
manufacturing scale bioreactors 
  
12:10 AM – 12:35 PM  Talk 24: Weichang Zhou (WuXi AppTec) 
Scale-up and scale-down challenges for a high density long-term 
perfusion suspension cell culture in large-scale single use bioreactors 
 
12:35 PM – 1:30 PM            Pick-up Box Lunches 
  
1:30 PM – 5:30 PM             Networking / Free Time 
  
5:30 PM – 7:00 PM             Workshops (3 in parallel) 
  
Workshop 4: Next generation manufacturing design: Batch to 
continuous  (Fiesta 9, 11, 12) 
Facilitators: Chetan Goudar (Amgen) and Rashmi Kshirsagar (Biogen) 
Sponsored by Genzyme 
 
Workshop 5: Empowering the next generation of cell culture scientists 
and engineers: Training and funding  (Fiesta 10, 13, 14) 
Facilitators: Matt Croughan (KGI), Anne Robinson (Tulane University) 
and Gene Schaefer (Janssen R&D) 
Sponsored by Eppendorf, Inc. 
 
Workshop 6: Lessons learned on quality by design approach through 
process development and characterization  (Flores 6, 7, 8) 
Facilitators: Thomas Link (Roche) and Vijay Janakiraman (Merck) 
Sponsored by Bristol-Myers Squibb 
 
7:00 PM – 9:00 PM              Dinner (All Grass Area) 
  
9:00 PM – 10:30 PM           Poster Session (Authors of even-numbered posters are asked to 
stay with their posters) 
    Sponsored by Lonza Biologics plc, Novo Nordisk A/S and MilliporeSigma 
  
  
Wednesday, May 11, 2016 
 
6:30 AM – 8:00 AM             Breakfast Buffet 
 
8:00 AM – 9:50 AM             Session 6a: Impact of Process Conditions on Product Quality 
     Sponsored by Thermo Fisher Scientific 
 
8:00 AM – 8:05 AM  Introduction – Session Chairs 
         Thomas Ryll (Immunogen) 
         Susan Sharfstein (SUNY Polytechnic Institute) 
  
8:05 AM – 8:10 AM  Poster Highlight for Impact of process conditions on product 
Quality (Session 6) 
Karin Anderson (Pfizer) 
Impact of culture conditions and cell age on sequence variant levels in 
monoclonal antibody biotherapeutics 
 
8:10 AM – 8:35 AM  Talk 25: Jose C. Menezes (Lisbon University) 
Bioanalytical comparability of biotechnology products subject to changes 
in their manufacturing process 
  
8:35 AM – 9:00 AM  Talk 26: David Bruehlmann (Merck Serono SA and University of 
    Würzburg) 
The potential of small molecules to modulate glycosylation by media 
design 
  
9:00 AM – 9:25 AM  Talk 27: Gyun Min Lee (KAIST) 
Factors affecting the sialylation of Fc- fusion protein in recombinant CHO 
cell culture 
  
9:25 AM – 9:50 AM  Talk 28: Sigma S. Mostafa (KBI BioPhama) 
Optimization of glycosylation and charge distribution through culture 
parameters and supplements 
 
9:50 AM – 10:20 AM           Coffee Break / Networking 
 
10:20 AM – 11:15 AM         Session 6b: Impact of Process Conditions on Product Quality 
  
10:20 AM – 10:25 AM  Continuation – Session Chairs 
Thomas Ryll (Immunogen) 
Susan Sharfstein (SUNY Polytechnic Institute)  
  
10:25 AM – 10:50 AM  Talk 29: Masaru Shiratori (Genentech) 
Identification of cell culture levers to lower trisulfide modifications in 
monoclonal antibodies produced in CHO cell culture 
  
10:50 AM – 11:15 AM  Talk 30: Sven Markert (Roche Diagnostics GmbH) 
From observation to control: Using cell culture automation for enhanced 
product quality optimization 
  
11:15 AM – 12:15 PM   Keynote – Jan Hillson (Momenta Pharmaceuticals) 
                                 Cell culture engineering and biosimilars: The physician’s 
    perspective 
Wednesday, May 11, 2016 (continued)
 
12:15 PM – 1:45 PM           Lunch 
 
1:45 PM – 2:15 PM             Sinacore Award – Huoug Le (Amgen)  
Evaluation of public genome references for RNA-seq data analysis 
in Chinese hamster ovary cells 
  
2:15 PM – 3:15 PM          Session 7a: Advanced Cell Culture Process Control 
  
2:15 PM – 2:20 PM  Introduction – Session Chairs 
Raghavan Venkat (MedImmune) 
Mike Butler (University of Manitoba) 
  
2:20 PM – 2:25 PM  Poster Highlight for Advanced Cell Culture Process Control 
(Session 7) 
Sha Sha (University of Massachusetts Lowell) 
Real time prediction and control of glycoform profile of mammalian cell 
cultures using in silicoglycosylation model coupled with extracellular 
metabolites 
  
2:25 PM – 2:50 PM  Talk 31: Bhanu Chandra Mulukutla (Pfizer) 
Systems Analysis of CHO cell metabolism for enhanced fed-batch 
process performance: Identification of novel growth inhibitors and their 
control 
  
2:50 PM – 3:15 PM  Talk 32: Catarina Brito (iBET) 
3D tumor models with defined cellular and physico- chemical 
components: Impact of recapitulative tumor microenvironment on 
disease progression 
 
3:15 PM – 3:45 PM              Coffee Break / Networking 
  
3:45 PM – 5:25 PM             Session 7b: Advanced Cell Culture Process Control 
  
3:45 PM – 4:10 PM   Talk 33: Veronique Chotteau (KTH Royal Institute of Technology) 
Poly-pathway model approach: Simulation of multiple metabolic states 
  
4:10 PM – 4:35 PM  Talk 34: Seongkyu Yoon (University of Massachusetts Lowell) 
Real time prediction and control of glycoform profile of mammalian cell 
cultures using in silico glycosylation model coupled with extracellular 
metabolites 
  
4:35 PM – 5:00 PM  Talk 35: Stephen Goldrick (UCL/MedImmune) 
Application of multivariate data analysis in the monitoring and control of 
mammalian cell processes 
  
5:00 PM – 5:25 PM  Talk 36: John Smelko (Biogen) 
Implementation of Raman spectroscopy at manufacturing scale: 
Overcoming modeling challenges while implementing advanced process 
control 
 
5:25 PM – 6:30 PM            Networking / Free Time 
  
Wednesday, May 11, 2016 (continued)
 
6:30 PM – 9:00 PM           Dine-Around Town (transportation provided) 
  
9:00 PM – 10:30 PM         Poster Session (Authors of odd-numbered posters are asked to 
stay with their posters)     
Sponsored by Solentim Ltd. and Takeda 
  
Thursday, May 12, 2016
 
6:30 AM – 8:00 AM             Breakfast Buffet 
 
Organizing Committee Breakfast Meeting (Diego Rivera Room) 
  
8:00 AM – 9:45 AM             Session 8a: Application of ‘Omics and other Technologies for 
    Accelerating and Enhancing Bioprocess Development 
  
8:00 AM – 8:05 AM  Introduction – Session Chairs 
Chetan Goudar (Amgen) 
Hal Alper (University of Texas, Austin) 
  
8:05 AM – 8:30 AM   Talk 37: Jamey D. Young (Vanderbilt University) 
Application of 13C flux analysis to identify high-productivity CHO 
metabolic phenotypes 
  
8:30 AM – 8:55 AM   Talk 38: Amanda Lewis (Bristol-Myers Squibb) 
Understanding and controlling sialyation in a CHO fusion protein at lab 
and manufacturing scale using targeted omics techniques 
  
8:55 AM – 9:20 AM   Talk 39: Markus Michael Mueller (Boehringer Ingelheim Pharma 
    GmbH) 
Targeting product quality: Where systems biotechnology and process 
design meet 
  
9:20 AM – 9:45 AM   Talk 40: Neil Templeton (Merck) 
Fluxomics: The integration of metabolic flux analysis (MFA) with 
multivariate data analysis (MVDA) to identify key process parameters for 
CHO cell culture 
 
9:45 AM – 10:15 AM           Coffee Break / Networking 
  
10:15 AM – 12:05 AM         Session 8b: ‘Omics Applications 
  
10:15 AM – 10:40 AM  Talk 41: Chapman Wright (Biogen) 
Biotherapeutic development in the 'Omics Age: The CHO genome and 
beyond 
  
10:40 AM – 11:05 AM  Talk 42: Dong-Yup Lee (National University of Singapore) 
Mammalian systems biotechnology: An integrative framework for 
combining in silico modeling and multi-Omics datasets in different CHO 
parental cell lines 
 
11:05 AM – 12:05 PM    Keynote – Michael Jensen (Juno Therapeutics)                                                               
    Next Gen CAR T-cells 
  
12:05 PM – 1:45 PM           Lunch 
  
  
Thursday, May 12, 2016 (continued) 
 
Two Parallel Oral Sessions 
 
1:45 PM – 3:30 PM            Session 9: Non-Protein Products (Fiesta 1-8) 
  
1:45 PM – 1:50 PM  Introduction — Session Chairs 
        Chris Ramsborg (Juno Therapeutics) 
        Bill Miller (Northwestern University) 
  
1:50 PM – 2:15 PM  Talk 43: Alvin W. Nienow (University of Loughborough) 
Agitation strategies for the culture and detachment of human 
mesenchymal stem cells (hMSCs) from microcarriers in multiple 
bioreactor platforms 
  
2:15 PM – 2:40 PM  Talk 44: E. Terry Papoutsakis (University of Delaware) 
Cell-derived microparticles for cell therapy, cargo delivery, and 
applications in CHO-cell biotechnology 
  
2:40 PM – 3:05 PM   Talk 45: Francesc Gòdia (Universitat Autònoma de Barcelona) 
Intracellular characterization of Gag-GFP VLP production upon PEI-
mediated transient transfection of HEK 293 cells 
  
3:05 PM – 3:30 PM  Talk 46: Rachel Legmann (Pall Life Sciences) 
Industrialization of adenoviral vector production in fixed bed 
bioreactor and amplification of primary liver cells in Xpansion® 
bioreactor: Autologous insulin producing cells for the treatment 
of diabetes, from bench to clinical scale 
  
1:45 PM – 3:30 PM          Session 10: Applications of QbD & PAT for Cell Culture (Fiesta 9-13) 
     Sponsored by Regeneron Pharmaceuticals, Inc. 
 
 1:45 PM – 1:50 PM  Introduction — Session Chairs 
Ashraf Amanullah (aTyr Pharma) 
Rob Thomas (Loughborough University) 
  
1:50 PM – 2:15 PM  Talk 47: Melissa S. Mun (Genentech) 
A quality by design (QbD) approach to cell culture process 
characterization 
  
2:15 PM – 2:40 PM  Talk 48: Michael Borys (Bristol- Myers Squibb) 
Incorporation of QbD elements into the development and 
characterization of a second generation process 
  
2:40 PM – 3:05 PM   Talk 49: Mathieu Streefland (Merck) 
Development of a process analytical technology (PAT) infrastructure for 
future biologics upstream processing 
 3:05 PM – 3:30 PM  Talk 50: Girish J Pendse (Eli Lilly) 
Use of quality by design principles for development of upstream process 
control strategy 
  
3:30 PM – 4:00 PM              Coffee Break / Networking 
  
Thursday, May 12, 2016 (continued) 
 
4:00 PM – 5:30 PM             Workshops (3 in parallel)  
     
Workshop 7: Applications of omics technologies  
Facilitators: Erdmann Rapp (Max Planck Institute) & Manuel Carrondo 
(iBET) (Fiesta 9-13) 
Sponsored by Amgen 
 
Workshop 8: Modulating product quality through cell culture process 
Facilitators: Kara Calhoun (Genentech) and Shyamsundar 
Subramanian (Teva) (Fiesta 1-8) 
Sponsored by Lilly 
 
Workshop 9: Opportunities for and challenges of process transfer and 
Scale-up (Flores 1, 2, 3) 
Facilitators: Gayle Derfus (Gilead) and Arthi Narayanan (Genentech) 
Sponsored by MilliporeSigma 
  
5:30 PM – 6:00 PM             Coffee Break / Networking 
  
6:00 PM – 7:00 PM             CCE Award Lecture — Jeff Chalmers (Ohio State University) 
 
7:00 PM – 7:30 PM           Reception (Flores Foyer and Veranda) 
 
7:30 PM – 10:30 PM           Banquet (Flores 4-8) 
    Sponsored by Genentech 
     
 Presentation of Poster Awards 
 
 Presentation of Cell Culture Engineering Award 
 
 Roast of CCE Award Winner – Konstantin Konstantinov (Codiak 
Biosciences) 
 
 Announcement of Chairs for CCE XVI 
 
 Announcement of Upcoming ECI Conferences  
 
 Closing Remarks by Conference Chairs  
 
Friday, May 13, 2016 
  
6:30 AM – 8:30 AM            Breakfast Buffet 
  
8:30 AM – 9:30 AM            Departures 
Poster Presentations 
 
Session I: Cell Line Development Advances 
 
1.  Automated, high throughput imaging during cell line development to increase the 
assurance of clonality 
David Shaw, Genentech, Inc., USA 
 
2.  Establishing a robust two-step cloning strategy for the generation of cell lines with a 
high probability of monoclonality 
Alison Young, Fujifilm Diosynth Biotechnologies, United Kingdom 
 
3.  Proof that can travel - documented clonality report for regulatory submission 
Paul Miller, Solentim Inc, United Kingdom 
 
4.  Insight into single cell cloning in serum-free media 
Tsuyoshi Yamaguchi, Kyowa Hakko Kirin Co., Ltd., Japan 
 
5.  Karyotype-based analysis of cell line instability and clonality in CHO cells 
Jong Youn Baik, University of Delaware, USA 
 
6.  Assessment of genomic instability in Chinese Hamster ovary (CHO) cells 
Sabine Vcelar, ACIB GmbH, Austria 
 
7.  Identifying low-Level sequence variants via next generation sequencing to aid stable 
CHO cell line screening 
Sheng Zhang, AbbVie, USA 
 
8.  Time course of transcription and chromatin states during batch culture in Chinese 
Hamster ovary cells 
Inmaculada Hernandez, Austrian Center of Industrial Biotechnology, Austria 
 
9.  Prediction of stable and transient expression of recombinant proteins from CHO cells 
based upon translational reprogramming 
Charlotte Godfrey, University of Kent, United Kingdom 
 
10.  Generation of a stable pluripotent cell line from Chinese Hamster embryonic 
fibroblasts 
Dong Seong Cho, University of Minnesota, USA 
 
11.  Microfluidic accelerated evaluation of CHO cell clones by perfusion of fed-batch 
conditioned media 
Darek Sikorski, University of British Columbia, Canada 
 
12.  Genome-wide RNAi screen for improved functional expression of recombinant 
proteins from HEK 293 cells 
Joseph Shiloach, NIDDK, USA 
 
13.  Bridging the gap of screening and scale up in CHO, hybridoma, HEK293 and other 
cell lines: Single use optimum growth flasks 30mL-5L flasks with transfer caps, and 
ports 
Sam Ellis, Thomson Instrument Company, USA 
 
 
 
14.  Sub-physiological culture temperature boosts expression levels of membrane 
proteins in CHO cells 
Sampath Kumar, Adimab LLC, USA 
 
15.  Varied productivity according to the differences between targeted locations of 
antibody expression vectors in Chinese Hamster ovary cells 
Noriko Yamano, Tokushima University, Japan 
 
16.  Targeted integration of multiple active sites in CHO genome for rapid generation of 
stable and high monoclonal antibody producing cell lines 
Yuansheng Yang, Bioprocessing Technology Institute, Singapore 
 
17.  Identifying opportunities in cell engineering for the production of ‘difficult to express’ 
recombinant proteins 
Hirra Hussain, The University of Manchester, United Kingdom 
 
18.  CHO-K1 host cell engineering strategy enabling the establishment of strains 
producing higher yields of recycling antibodies 
Hisahiro Tabuchi, Chugai Pharmaceutical, Japan 
 
19.  Flow cytometry screening strategy for the enrichment of high-producing Chinese 
Hamster ovary cells for monoclonal antibody manufacturing 
Takeshi Okumura, Daiichi Sankyo Co., Ltd., Japan 
 
20.  Reduction of metabolic waste products, ammonia and lactate, through the coupling 
of GS selection and LDH-A down-regulation in CHO cells 
Soo Min Noh, KAIST, South Korea 
 
21.  Cre-loxP-controlled cell-cycle checkpoint engineering in Chinese Hamster ovary cells 
Takeshi Omasa, Osaka University, Japan 
 
22.  Expression of glycoproteins with excellent pharmacokinetic properties on the novel 
CAP-Go expression platform 
Silke Wissing, CEVEC Pharmaceuticals, Germany 
 
23.  An integrated cell line development platform for generation of high yielding CHO 
stable cell lines expressing a stabilized trimeric pre-fusion RSV F recombinant viral 
glycoprotein 
Richard Schwartz, Vaccine Research Center, NIAID, NIH, USA 
 
24.  Development of hyper osmotic resistant CHO host cells 
Yasuharu Kamachi, Takeda Pharmaceutical Company Limited, Japan 
 
25.  Genetic engineering of CHO cells for viral resistance to MMV: Targeting virus 
binding, internalization, intracellular trafficking and transport to nucleus 
Joaquina Mascarenahs, SAFC, USA 
 
26.  Accelerated homology-directed targeted integration of transgenes in CHO cells via 
CRISPR/Cas9 and fluorescent enrichment 
Jae Seong Lee, Technical University of Denmark, Denmark 
 
27.  CRISPR-CAS9 knockout library for CHO 
Lasse E. Pedersen, Technical University of Denmark, Denmark 
 
 
28.  Glycoengineering of Chinese Hamster ovary cell for modulating glycoprotein N-
linked sialylation 
Chengyu Chung, Johns Hopkins University, USA 
 
29.  Re-programming CHO cell metabolism using miR-23 tips the balance towards a 
highly productive phenotype 
Niall Barron, Dublin City University, Ireland 
 
30.  A novel platform for high throughput cell line screening & development 
Maria Wendt, Genedata AG, Switzerland 
 
31.  Cell Express 100TM - A robust, simple and cost effective alternative to high-
throughput automated platforms for cell line development 
Raj Kumar Kunaparaju, USHA Bio-tech, India 
 
 
Session II: Impact of Process Conditions on Product Quality 
 
32.  Changes in product quality – what is comparable “enough” and what is “similar 
enough?” 
David K. Robinson, Robinson Vaccines and Biologics LLC, USA 
 
33.  Improving the productivity and product quality of antibodies expressed from a CHO 
transient system 
Athena Wong, Genentech, Inc., USA 
 
34.  A systematic development approach to optimize and control biopharmaceutical 
product quality 
Min Zhang, Fujifilm Diosynth Biotechnologies, USA 
 
35.  Strategies for optimizing a cell culture platform to achieve high recombinant protein 
titer without impacting product quality 
Natarajan Vijayasankaran, Genentech, Inc., USA 
 
36.  Impact of harvest conditions on the glycosylation profile of a therapeutic antibody 
Raghavan Venkat, MedImmune LLC, USA 
 
37.  Investigating the impact of process optimization on productivity, product quality, cell 
metabolism, and intracellular environment 
Shailendra Singh, MedImmune, USA 
 
38.  Enhancing enveloped viral particles production by targeted supplementation design: 
Releasing bottlenecks in IC-BEVS 
António Roldão, iBET, Portugal 
 
39.  Efforts to reduce impact of media variability on product quality for a commercial 
perfusion process 
Nirel Rillera, BioMarin Pharmaceutical Inc., USA 
 
40.  Bioreactor perfusion via single-use centrifugation has fewer product quality 
implications than tangential flow filtration 
Rustin Shenkman, Shire, USA 
 
41.  Impact of culture conditions and cell age on sequence variant levels in monoclonal 
antibody biotherapeutics 
Karin Anderson, Pfizer, Inc., USA 
42.  Evaluation of product antibody (mAb) heterogeneity in non-clonal cell pools for early 
pre-clinical development 
Gabi Tremml, Bristol-Myers Squibb, USA 
 
43.  A biphasic cultivation strategy to optimize protein expression and minimize 
aggregation of the final product 
Andreas Castan, GE Healthcare, Ireland 
 
44.  Adjusting product quality attributes of a biosimilar using process levers 
Brett Belongia, Momenta Pharmaceuticals, USA 
 
45.  Improving the metabolic efficiency of mammalian cells and its impact on 
glycoproteins quality 
Eric Karengera, École Polytechnique de Montréal, Canada 
 
46.  CHO cell culture process impacts monoclonal antibody trisulfide modification and 
sulfhydryl-drug conjugation 
Michael Hippach, Agensys, Inc, USA 
 
47.  Critical process parameter identification using the ambr15(tm) for process 
characterization 
Matthew Zustiak, Patheon Biologics, USA 
 
48.  Influence of cultivation parameters or supplement on product qualities and culture 
performances during perfusion 
Kyu-Yong Kim, LG Life Sciences, Ltd., South Korea 
 
 
Session III: Advanced Cell Culture Process Controls and Modeling 
 
49.  Reduction of N-glycan profile variation by using capacitance probes for optimized 
process control 
Christoffer Bro, Biogen, Denmark 
 
50.  Advanced process monitoring and feedback control to enhance cell culture process 
production and robustness 
An Zhang, Biogen, USA 
 
51.  Monitoring live stem cells in suspension and attached to carriers in conventional and 
single use bioreactors 
John Carvell, Aber Instruments Ltd., United Kingdom 
 
52.  Monitoring live biomass in disposable bioreactors in range of vessel formats 
Dan Kopec, Sartorius Stedim Biotech, Germany 
 
53.  Use of an automated, integrated laboratory environment to enable predictive 
modeling approaches for identifying critical process parameters and controlling key 
quality attributes 
Brandon J. Downey, Bend Research, Inc., USA 
 
54.  Softsensors: New approach for process monitoring cell growth in small scale 
fermentation systems 
Wolfgang Paul, Roche Innovation Center, Germany 
 
55.  Advancement of cell culture process understanding and control through real-time 
multivariate process monitoring, use of statistical process modes and deployment of 
process analytical technologies 
Patrick O. Gammell, Amgen, USA 
 
56.  Agent-based model predictive framework to control cell culture bioreactors 
Elif S. Bayrak, Amgen Inc., USA 
 
57.  Kinetic physico-chemical model for cell culture processes – applications and 
opportunities 
Natraj Ram, AbbVie, USA 
 
58.  Accelerate cell culture development using the modular automated sampling 
technology (MASTTM) platform in an integrated bioprocess lab environment 
Clinton B. Pepper, Bend Research, USA 
 
59.  Development of bioreactor auto-sampling system for real time product quality 
monitoring in mammalian cell culture 
Meena George, Boehringer Ingelheim Fremont Inc, USA 
 
60.  Lensless imaging for continuous CHO viable cell density monitoring in bioreactors 
Geoffrey Esteban, IPRASENSE, France 
 
61.  Continuous suspension cell culture monitoring in bioreactors using quantitative 
imaging 
Ann D’Ambruoso, Applikon, USA 
 
62.  Investigating the reverse Warburg effect: How high extracellular lactate alters breast 
cancer metabolism 
Daniel C. Odenwelder, Clemson University, USA 
 
63.  Real time prediction and control of glycoform profile of mammalian cell cultures 
using in silicoglycosylation model coupled with extracellular metabolites 
Sha Sha, University of Massachusetts Lowell, USA 
 
64.  A stochastic model to study genetic and metabolic effects on N-linked protein 
glycosylation 
Philipp N. Spahn, University of California, San Diego, USA 
 
65.  CHO-specific recombinant protein glycosylation reaction network 
Benjamin G. Kremkow, University of Delaware, USA 
 
66.  Controller design for effective glycosylation control in mAbs 
Devesh Radhakrishnan, University of Delaware, USA 
 
67.  Elucidating glycosylation pattern of protein produced in mammalian cells 
Tung S. Le, University of Minnesota, USA 
  
68.  Poly-pathway model approach: Simulation of multiple metabolic states 
Erika Hagrot, KTH Royal Institute of Technology, Sweden 
 
 
Session IV: Scale-Up and Scale-Down Challenges for Cell Culture Based Manufacturing 
 
69.  Improved scale-down model development case study for raw materials screening 
Angela Au, Bristol-Myers Squibb, USA 
70.  Characterization of TAP Ambr250 disposable bioreactors as a reliable scale-down 
model for biologics process development 
Ping Xu, Bristol-Myers Squibb, USA 
 
71.  Metabolomic analysis for scale-down model improvement 
Eric Garr, Bristol-Myers Squibb, USA 
 
72.  Demonstrating process performance comparability of the Keytruda® upstream 
process after transfer and scale-up to different manufacturing sites 
Jürgen van de Lagemaat, MSD, Netherlands 
 
73.  Challenges in the use of scale-down models for understanding and mitigating 
process variations of a monoclonal antibody production process 
A. Peter Russo, Merck & Co., Inc., USA 
 
74.  Scale-up in the single use age: Does geometry matter? 
Colin Jaques, Lonza Biologics, United Kingdom 
 
75.  A rapid approach for basal and feed media optimization in ambr® 15 bioreactors 
Michael Gillmeister, Lonza, USA 
 
76.  Tubespins as a suitable scale-down model of 2L high cell density bioreactors for 
CHO cell culture 
Natalia Gomez, Amgen , USA 
 
77.  Process scale-up issues: Relics of the past or continues to cause major headaches 
Sadettin Ozturk, MassBiologics, USA 
 
78.  Novel, efficient scale-up of inclined settlers for perfusion bioreactor cultures 
Dhinakar S. Kompala, Sudhin Biopharma Company, USA 
 
79.  Bioreactor scale-up harmonization - From process development to manufacturing 
Claudia Berdugo-Davis, Cook Pharmica LLC, USA 
 
80.  Scale-up and scale-down topics facing the industry 
Markus M. Mueller, Boehringer Ingelheim Pharma GmbH & Co.KG, Germany 
 
81.  Case study for improved process robustness at manufacturing scale for a 
mammalian cell culture process: Troubleshooting medium preparation and gas 
entrance velocity effects 
Robin Luo, Boehringer Ingelheim, USA 
 
82.  Performance consistency of fed-batch cultures across multiple systems used in 
upstream process development 
Matthieu Stettler, Merck Serono, Switzerland 
 
83.  Overcoming scale-up challenges with a non-robust cell line 
Sigma Mostafa, KBI Biopharma, USA 
 
84.  Application of online CO2 monitoring to enable a better understanding of cell culture 
performance variation between GMP-scale and scaled-down bioreactors 
Ting-Kuo Huang, Genentech Inc., USA 
 
85.  Establishing a pH measurement reference method for site/process transfer purposes 
Meg Tung, Genentech Inc., USA 
 
86.  Case study: Lessons learned during tech transfer at a multi-product legacy launch 
facility 
Arthi Narayanan, Genentech Inc., USA 
 
87.  Scale down model in industrial cell culture processes – A powerful tool to ensure 
reliable production 
Marco Jenzsch, Roche Pharma Biotech, Germany 
 
88.  Advances in bioreactor scale-down modeling using Process Analytical Technology 
(PAT) 
Liying Yang, Astrazeneca, USA 
 
89.  Challenges of scale down model for disposable bioreactors: Case studies on growth 
& product quality impacts 
Jincai Li, WuXi AppTec, China 
 
90.  A holistic approach to the scale-up of a microcarrier-based perfusion cell culture 
process for the production of a therapeutic enzyme 
Jin Yin, Genzyme, A Sanofi Company, USA 
 
91.  Bioreactor process improvements in a legacy perfusion-based process 
Mustafa Hanif, Genzyme, A Sanofi Company, USA 
 
92.  Preferentially selecting cellular metabolism and improving productivity by controlling 
do and Pco2 
Sofie Goetschalckx, Genzyme, A Sanofi Company, USA 
 
93.  Challenges and their resolutions during process development and tech transfer of a 
late stage bispecific antibody product 
Marcella Yu, Sanofi, USA 
 
94.  Scalability of the Mobius® single-use bioreactor from bench to clinical scale: 
Examination of key engineering parameters and robustness 
Lee Madrid, EMD Millipore, USA 
 
95.  Single-step flask to 250 L cell culture with a hybrid mixing single-use bioreactor 
Nephi Jones, Thermo Fisher Scientific, USA 
 
 
Session V: Integrated Continuous Process Development for Cell Culture 
 
96.  Rapid development of a perfusion process with high productivity 
Sen Xu, Merck Research Laboratories, USA 
 
97.  Integrated continuous bioprocessing - a gold mine for cell culture process 
understanding? 
Mats Akesson, Novo Nordisk A/S, Denmark 
 
98.  Perfusion media development and evaluation with spin tube and ambr15 high-
throughput small-scale models 
Yang Wang, Thermo Fisher Scientific, Inc., USA 
 
99.  Process intensification through integration of upstream perfusion cell culture with 
downstream continuous chromatography in monoclonal antibody production 
Andreas Castan, GE Healthcare, Sweden 
 
100. Modeling perfusion for medium component optimization using ambr15TM 
Delia Lyons, SAFC, USA 
 
101. Small-scale comparison of pseudoperfusion feeding strategies using basal and 
concentrated feed media 
Leda R. Castilho, Federal University of Rio de Janeiro, Brazil 
 
102. Towards integrated continuous viral vaccines production using two-stage bioreactor 
systems 
Felipe Tapia, Max Planck Institute Magdeburg, Germany 
 
103. Development of a qualtiy driven integrated continuous biomanufacturing process 
Daniel Karst, ETH Zurich, Switzerland 
 
104. mAb product consistency in long duration microfiltration-based CHO perfusion 
process 
Douglas Rank, EMD Millipore, USA 
 
105. Toward development of continuous bioprocesses: Comparison of fed-batch and 
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